| Cancer risk and oxidative DNA damage in man S Loft, HE Poulsen Journal of molecular medicine 74, 297-312, 1996 | 1379 | 1996 |
| Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation ML Hansen, R Sørensen, MT Clausen, ML Fog-Petersen, J Raunsø, ... Archives of internal medicine 170 (16), 1433-1441, 2010 | 1093 | 2010 |
| The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial MI Covas, K Nyyssönen, HE Poulsen, J Kaikkonen, HJF Zunft, ... Annals of internal medicine 145 (5), 333-341, 2006 | 1060 | 2006 |
| Clinical relevance of biomarkers of oxidative stress J Frijhoff, PG Winyard, N Zarkovic, SS Davies, R Stocker, D Cheng, ... Antioxidants & redox signaling 23 (14), 1144-1170, 2015 | 990 | 2015 |
| Guidelines for measuring reactive oxygen species and oxidative damage in cells and in vivo MP Murphy, H Bayir, V Belousov, CJ Chang, KJA Davies, MJ Davies, ... Nature metabolism 4 (6), 651-662, 2022 | 792 | 2022 |
| Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index S Loft, K Vistisen, M Ewertz, A Tjønneland, K Overvad, HE Poulsen Carcinogenesis 13 (12), 2241-2247, 1992 | 779 | 1992 |
| Olive oil and health: summary of the II international conference on olive oil and health consensus report, Jaén and Córdoba (Spain) 2008 J López-Miranda, F Pérez-Jiménez, E Ros, R De Caterina, L Badimón, ... Nutrition, metabolism and cardiovascular diseases 20 (4), 284-294, 2010 | 759 | 2010 |
| Role of oxidative DNA damage in cancer initiation and promotion HE Poulsen, H Prieme, S Loft European journal of cancer prevention, 9-16, 1998 | 559 | 1998 |
| Establishing the background level of base oxidation in human lymphocyte DNA: results of an interlaboratory validation study CM Gedik, A Collins, J Dubois, P Duez, L Kouegnigan, JF Rees, S Loft, ... Faseb Journal 19 (1), 82-84, 2005 | 515 | 2005 |
| Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study RM Salonen, K Nyyssönen, J Kaikkonen, E Porkkala-Sarataho, ... Circulation 107 (7), 947-953, 2003 | 479 | 2003 |
| Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3‐year progression of carotid atherosclerosis JT Salonen, K Nyyssönen, R Salonen, HM Lakka, J Kaikkonen, ... Journal of internal medicine 248 (5), 377-386, 2000 | 449 | 2000 |
| Fluvoxamine is a potent inhibitor of cytochrome P4501A2 K Brøsen, E Skjelbo, BB Rasmussen, HE Poulsen, S Loft Biochemical Pharmacology 45 (6), 1211-1214, 1993 | 445 | 1993 |
| Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine U Jeppesen, LF Gram, K Vistisen, S Loft, HE Poulsen, K Brøsen European journal of clinical pharmacology 51, 73-78, 1996 | 429 | 1996 |
| Biomarkers HR Griffiths, L Møller, G Bartosz, A Bast, C Bertoni-Freddari, A Collins, ... Molecular aspects of medicine 23 (1-3), 101-208, 2002 | 426 | 2002 |
| Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure GH Gislason, JN Rasmussen, SZ Abildstrom, TK Schramm, ML Hansen, ... Archives of internal medicine 169 (2), 141-149, 2009 | 392 | 2009 |
| Are we sure we know how to measure 8-oxo-7, 8-dihydroguanine in DNA from human cells? AR Collins, J Cadet, L Mőller, HE Poulsen, J Vina Archives of Biochemistry and Biophysics 423 (1), 57-65, 2004 | 379 | 2004 |
| Occurrence of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Patients Is Associated with the Oxidative Stress Caused by Chronic Lung Inflammation O Ciofu, B Riis, T Pressler, HE Poulsen, N Høiby Antimicrobial agents and chemotherapy 49 (6), 2276-2282, 2005 | 356 | 2005 |
| Oxidative stress BB Halliwell, HE Poulsen Cigarette smoke and oxidative stress, 1-4, 2006 | 348 | 2006 |
| European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS) J Egea, I Fabregat, YM Frapart, P Ghezzi, A Görlach, T Kietzmann, ... Redox biology 13, 94-162, 2017 | 341 | 2017 |
| The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated … EJM van Bommel, MHA Muskiet, MJB van Baar, L Tonneijck, MM Smits, ... Kidney international 97 (1), 202-212, 2020 | 328 | 2020 |
Steffen LoftUniversity of Copenhagen, Department of Public HealthEmail được xác minh tại sund.ku.dk